Back

Gene therapy for catecholaminergic polymorphic ventricular tachycardia (CPVT): IND-enabling data and design of the ARTEMIS Phase 1b clinical trial

12 April 2026 (08:00 - 15:30)
Organised by: Logo
Congress Presentation Part of: Congenital heart disease and channelopathies Genetic Aspects of Arrhythmias EHRA Premium Access EHRA 2026 European Heart Rhythm Association (EHRA)

About the speaker

Photo
Doctor Afshin Farzaneh-Far

Solid Biosciences, Boston (United States of America)

4 More presentations in this session

Presentation thumbnail
Progression of atrioventricular valve regurgitation in patients with and without atrial fibrillation
Mr M. Koechlin (Basel, CH)
Abstract Slides Video
Presentation thumbnail
Atrioventricular junction ablation in patients with congenital heart disease: a multicenter study on procedural characteristics and outcomes
Mr N. Ramdat Misier (Rotterdam, NL)
Abstract Slides Video
Presentation thumbnail
Phenotypic heterogeneity in Andersen-Tawil syndrome: Insights from the International ATS Registry
Mrs P. Bhardwaj (Copenhagen, DK)
Abstract Slides Video
Presentation thumbnail
Genetic variability in Andersen-Tawil syndrome: insights from the international ATS Registry
Doctor S. Jacobsen (Copenhagen, DK)
Abstract Slides Video

Access the full session

Session thumbnail
Congenital heart disease and channelopathies
Video

The Event

Event poster

EHRA 2026

12 April - 14 April 2026
You may be interested in
thumbnail
Congress Session
Congenital heart disease and channelopathies
thumbnail
Congress Session
Genetic cardiomyopathies and channelopathies: close to personalised treatment strategies?
thumbnail
Congress Session
Advances in gene therapy and gene editing in the heart and vasculature

ESC 365 is supported by

novartis Explore sponsored resources

ESC 365 is supported by

novartis Explore sponsored resources